No

Beta Blocker, Nonselective; Ophthalmic Agent, Antiglaucoma

Agent for lowering intraocular pressure in patients with chronic open-angle glaucoma

C

Bronchial asthma, sinus bradycardia, second and third degree A-V block, cardiac failure, cardiogenic shock, hypersensitivity to betaxolol or any component, pregnancy

Use with caution in patients with cardiac failure or diabetes mellitus, asthma, bradycardia, or A-V block

>10%: Ocular: Mild ocular stinging and discomfort, eye irritation

1% to 10%: Ocular: Blurred vision, browache

<1%: Bradycardia, A-V block, congestive heart failure, erythema, weakness, conjunctivitis, blepharitis, tearing, itching eyes, keratitis, photophobia, decreased corneal sensitivity, bronchospasm

Symptoms of overdose include bradycardia, hypotension, A-V block

Sympathomimetics (eg, epinephrine or dopamine), glucagon or a pacemaker can be used to treat the toxic bradycardia, asystole, and/or hypotension; initially, fluids may be the best treatment for toxic hypotension

No data reported

Beta-adrenoceptor-blocking agent; lacks intrinsic sympathomimetic activity and membrane-stabilizing effects and possesses only slight local anesthetic activity; mechanism of action of metipranolol in reducing intraocular pressure appears to be via reduced production of aqueous humor. This effect may be related to a reduction in blood flow to the iris root-ciliary body. It remains unclear if the reduction in intraocular pressure observed with beta-blockers is actually secondary to beta-adrenoceptor blockade.

Onset of action: less than or equal to 30 minutes

Maximum effects: ~2 hours

Duration of action: Intraocular pressure reduction has persisted for 24 hours following ocular instillation

Metabolism: Rapid and complete to deacetyl metipranolol, an active metabolite

Half-life, elimination: ~3 hours

Ophthalmic: Adults: Instill 1 drop in the affected eye(s) twice daily

None reported

None reported

No information available to require special precautions

No effects or complications reported

Intended for twice daily dosing; keep eye open and do not blink for 30 seconds after instillation; wear sunglasses to avoid photophobic discomfort

Monitor for systemic effect of beta-blockade

Solution, ophthalmic, as hydrochloride: 0.3% (5 mL, 10 mL)